- Home
- ELDN vs FENC Comparison
ELDN vs FENC Comparison
Compare ELDN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- FENC
- Stock Information
- Founded
- ELDN 2004
- FENC 1996
- Country
- ELDN United States
- FENC United States
- Employees
- ELDN N/A
- FENC N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELDN Health Care
- FENC Health Care
- Exchange
- ELDN Nasdaq
- FENC Nasdaq
- Market Cap
- ELDN 178.4M
- FENC 156.9M
- IPO Year
- ELDN N/A
- FENC 2001
- Fundamental
- Price
- ELDN $3.06
- FENC $7.93
- Analyst Decision
- ELDN Strong Buy
- FENC Strong Buy
- Analyst Count
- ELDN 1
- FENC 2
- Target Price
- ELDN $16.00
- FENC $13.00
- AVG Volume (30 Days)
- ELDN 214.2K
- FENC 103.7K
- Earning Date
- ELDN 05-14-2025
- FENC 05-13-2025
- Dividend Yield
- ELDN N/A
- FENC N/A
- EPS Growth
- ELDN N/A
- FENC N/A
- EPS
- ELDN N/A
- FENC N/A
- Revenue
- ELDN N/A
- FENC $30,912,000.00
- Revenue This Year
- ELDN N/A
- FENC N/A
- Revenue Next Year
- ELDN N/A
- FENC $58.65
- P/E Ratio
- ELDN N/A
- FENC N/A
- Revenue Growth
- ELDN N/A
- FENC N/A
- 52 Week Low
- ELDN $2.30
- FENC $3.96
- 52 Week High
- ELDN $5.54
- FENC $8.56
- Technical
- Relative Strength Index (RSI)
- ELDN 49.05
- FENC 66.43
- Support Level
- ELDN $2.96
- FENC $7.79
- Resistance Level
- ELDN $3.27
- FENC $8.34
- Average True Range (ATR)
- ELDN 0.17
- FENC 0.47
- MACD
- ELDN 0.02
- FENC 0.06
- Stochastic Oscillator
- ELDN 53.33
- FENC 75.98
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.